

PRESS RELEASE

Grenchen, April 9, 2015

Outstanding reliability in the early healing phase

A study of almost 3,000 Thommen Implants placed in patients showed an early failure rate of only 0.5% and a late failure rate of 0%¹. These results exceed not only the average retrospective outcomes recently published in an analysis by the Swedish National Register², but also those of the implant model with the lowest failure rates in this study. In a comparison of the survival rates of implants with two different implant surfaces¹ (hydrophobic and superhydrophilic), implants with the superhydrophilic INICELL[®] surface performed statistically significantly better and illustrated the reliability of the INICELL[®] surface in the early healing phase.

In a recent study by LeGac and Grunder published in the Dentistry Journal (No 3 (2015), 15-23), almost 3,000 Thommen ELEMENT[®] Implants were placed and surveyed over a test period of up to 6 years. Two different surfaces were featured in the study, one hydrophobic (TST) and one superhydrophilic (INICELL[®]), on identical implant designs. At the conclusion, no failures occurred after occlusal loading in any of the implants; this corresponds to a 0% late failure rate. However, an early failure rate of 1.5% was established for the hydrophobic implants. This early failure rate is statistically significantly higher than the outcomes of 0.5% with the superhydrophilic implants. The superhydrophilic surface was obtained by conditioning with INICELL[®] by Thommen Medical.

These outcomes appear only a few months after the publication of a retrospective study by the Swedish National Register, in which the results of implants placed in 2,765 patients were surveyed over a test period of 9 years. On average, the implants in the study achieved an early failure rate of 4.4% and an average late failure rate of 4.2%. Notably, the implant model in the study that was described as being the “best in their class” reported an early failure rate of 0.7% and late failure rate of 0.5%, a higher failure rate than with the Thommen Implants. Therefore, the results clearly illustrate the superior performance by Thommen implants over the other implant models in the Swedish National Register study.

Confidence is a commodity that can only be earned. The results achieved with the superhydrophilic INICELL[®] surface (0.5%, or 0%) prove, once again, the impressive reliability of Thommen INICELL[®] Implants. Superior performance in the early healing phase and long-term advantages can be achieved when using the INICELL[®] surface in everyday practice, providing the confidence and quality that clinicians deserve.

¹ O. Le Gac und U. Grunder. Six year survival and early failure rate of 2918 implants with hydrophobic and hydrophilic enossal surfaces. Dentistry Journal 2015, 3, 15-23, doi:10.3390/dj30x000x - <http://www.mdpi.com/2304-6767/3/1/15>.

² Derks et al. Effectiveness of implant therapy analyzed in a Swedish population: Early and late implant loss. J Dent Res 2014, Dez 11 - <http://www.ncbi.nlm.nih.gov/pubmed/25503901>

Contact

Thommen Medical AG
Neckarsulmstrasse 28
CH-2540 Grenchen
Tel. +41 61 965 90 20
Fax +41 61 965 90 21
presse@thommenmedical.com
www.thommenmedical.com

The press release is also available online:

<http://www.thommenmedical.com/en/company/media/press-releases.html>

About Thommen Medical

Thommen Medical develops, manufactures and sells high-quality products for dental implantology, mainly the Thommen Implant System and biomaterials. Swiss precision, innovation, and functional design form the basis for all of the company's products. Thommen Medical's headquarters and private manufacturing facility is located in Grenchen, Switzerland. Thommen Medical has subsidiaries in Switzerland, Germany, Austria, Benelux, United States and Canada, and is represented by distribution partners in most other major markets of Europe, Asia and the Middle East. It is currently a privately held company, with two private investor groups and Novartis being the majority stockholders.